These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34648371)

  • 1. Replication and single-cycle delivery of SARS-CoV-2 replicons.
    Ricardo-Lax I; Luna JM; Thao TTN; Le Pen J; Yu Y; Hoffmann HH; Schneider WM; Razooky BS; Fernandez-Martinez J; Schmidt F; Weisblum Y; Trüeb BS; Berenguer Veiga I; Schmied K; Ebert N; Michailidis E; Peace A; Sánchez-Rivera FJ; Lowe SW; Rout MP; Hatziioannou T; Bieniasz PD; Poirier JT; MacDonald MR; Thiel V; Rice CM
    Science; 2021 Nov; 374(6571):1099-1106. PubMed ID: 34648371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors.
    Luo Y; Yu F; Zhou M; Liu Y; Xia B; Zhang X; Liu J; Zhang J; Du Y; Li R; Wu L; Zhang X; Pan T; Guo D; Peng T; Zhang H
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A BSL-2 compliant mouse model of SARS-CoV-2 infection for efficient and convenient antiviral evaluation.
    Chen Z; Cui Q; Ran Y; Achi JG; Chen Z; Rong L; Du R
    J Virol; 2024 Jul; 98(7):e0050424. PubMed ID: 38899934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of viral propagation and drug response among SARS-CoV-2 VOCs using replicons capable of recapitulating virion assembly and release.
    Tian L; Liu Q; Pei R; Chen Y; Xu C; Tang J; Sun H; Liu K; Yang Q; Yang L; Li L; Zhang Y; Zhou Y; Shan C; Hu X; Chen X; Wang Y
    Virol Sin; 2022 Oct; 37(5):695-703. PubMed ID: 35781091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.
    Fahnøe U; Pham LV; Fernandez-Antunez C; Costa R; Rivera-Rangel LR; Galli A; Feng S; Mikkelsen LS; Gottwein JM; Scheel TKH; Ramirez S; Bukh J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities.
    Takazawa S; Kotaki T; Nakamura S; Utsubo C; Kameoka M
    Virus Res; 2023 Sep; 334():199176. PubMed ID: 37473963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Single-Cycle Infectious SARS-CoV-2 Virus Replicon Particle System for Use in Biosafety Level 2 Laboratories.
    Malicoat J; Manivasagam S; Zuñiga S; Sola I; McCabe D; Rong L; Perlman S; Enjuanes L; Manicassamy B
    J Virol; 2022 Feb; 96(3):e0183721. PubMed ID: 34851142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen.
    Liu S; Chou CK; Wu WW; Luan B; Wang TT
    J Virol; 2022 Mar; 96(6):e0221621. PubMed ID: 35080424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
    He X; Quan S; Xu M; Rodriguez S; Goh SL; Wei J; Fridman A; Koeplinger KA; Carroll SS; Grobler JA; Espeseth AS; Olsen DB; Hazuda DJ; Wang D
    Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33766889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Cell Culture Model for Inducible SARS-CoV-2 Replication.
    Wang X; Zhu Y; Wu Q; Jiang N; Xie Y; Deng Q
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Su WC; Chen ZY; Chang YS; Jeng KS; Le UNP; Chou YC; Kuo LL; Melano I; Jesse ; Wang WJ; Song YC; Li SR; Hung MC; Lai MMC; Lin CW
    Antiviral Res; 2023 Dec; 220():105744. PubMed ID: 37944823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles.
    Pu T; Ding C; Li Y; Liu X; Li H; Duan J; Zhang H; Bi Y; Cun W
    J Med Virol; 2020 Sep; 92(9):1609-1614. PubMed ID: 32275081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spike mutation D614G alters SARS-CoV-2 fitness.
    Plante JA; Liu Y; Liu J; Xia H; Johnson BA; Lokugamage KG; Zhang X; Muruato AE; Zou J; Fontes-Garfias CR; Mirchandani D; Scharton D; Bilello JP; Ku Z; An Z; Kalveram B; Freiberg AN; Menachery VD; Xie X; Plante KS; Weaver SC; Shi PY
    Nature; 2021 Apr; 592(7852):116-121. PubMed ID: 33106671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis.
    Wang L; Guzman M; Muñoz-Santos D; Honrubia JM; Ripoll-Gomez J; Delgado R; Sola I; Enjuanes L; Zuñiga S
    Front Cell Infect Microbiol; 2023; 13():1268227. PubMed ID: 37942479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon.
    Cheung PH; Ye ZW; Lui WY; Ong CP; Chan P; Lee TT; Tang TT; Yuen TL; Fung SY; Cheng Y; Chan CP; Chan CP; Jin DY
    J Med Virol; 2022 Dec; 94(12):6078-6090. PubMed ID: 35941087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation.
    Wang B; Zhang C; Lei X; Ren L; Zhao Z; Wang J; Huang H
    Virol Sin; 2021 Oct; 36(5):890-900. PubMed ID: 33835389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.